Clinical Trial Detail

NCT ID NCT02385669
Title A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Craig L Slingluff, Jr
Indications

melanoma

Therapies

6MHP vaccine

Ipilimumab

Age Groups: adult

No variant requirements are available.